Grow Therapy Raises $150M Series D for Mental Health Access

Grow Therapy has successfully closed a substantial $150 million Series D funding round, signaling robust investor confidence in its mission to broaden access to effective mental health services. The financing was spearheaded by existing backers TCV and Growth Equity at Goldman Sachs Alternatives, with significant participation from new investors BCI and Menlo Ventures. This infusion of capital also saw continued support from prominent firms including Sequoia, SignalFire, and Transformation Capital.

This latest funding underscores Grow Therapy's strategic advancements in forging critical alliances with health plans, employers, and health systems. The company's innovative approach, which empowers licensed providers with advanced tools for both in-person and virtual care, has demonstrably improved patient outcomes and provider efficiency. CEO and Co-founder Jake Cooper highlighted the round as a testament to the company's capacity to execute a high-impact strategy, making mental healthcare more attainable and effective.

The mental health technology sector is experiencing significant growth, driven by increasing awareness of mental well-being and the demand for accessible solutions. Grow Therapy has positioned itself at the forefront by facilitating over 10 million total therapy and medication management appointments to date, serving more than two million individuals nationwide. The platform boasts an impressive 85 Net Promoter Score (NPS), with nine out of ten clients recommending the service, reflecting a strong commitment to client satisfaction and care quality.

Since its Series C round in April 2024, Grow Therapy has rolled out several key enhancements. Providers benefit from significantly reduced documentation time, with AI-assisted notes cutting down administrative tasks by nearly 70% while maintaining high accuracy. For patients, the Grow mobile app offers free AI-guided tools for self-reflection between sessions, with consent-based insights shared with clinicians to optimize appointment time. Crucially, the platform has expanded its insurance network to cover over 125 health insurers, including Medicare and Medicaid, making care accessible to an estimated 220 million people. This broad coverage means clients on average pay just $21 per visit, with one in three receiving care at no cost.

The company's strategic partnerships are also expanding entry points to care. Grow Therapy is enhancing workplace mental health benefits by creating seamless transitions for employees from employer-sponsored programs to health insurance coverage, ensuring continuity of care with their chosen provider. This model offers nationwide access to vetted clinicians, flexible care options, and AI-driven support, all while aligning costs with employer expectations. Unlike traditional models, Grow Therapy charges only for delivered care, providing employers with a more predictable and confident investment in employee well-being.

The market for mental health solutions is rapidly evolving, with a clear demand for integrated, accessible, and outcome-driven platforms. Grow Therapy's success in securing this significant Series D funding, coupled with its demonstrable impact on patient access and provider efficiency, positions it as a leader in redefining mental healthcare delivery. The company's focus on measurable outcomes, as evidenced by 80% of clients seeing symptom improvement within 30 days, further solidifies its value proposition in a competitive and critical sector.